Dr Pawlyn speaks with ecancer at EHA 23 about the suitability of ASCT from older myeloma patients.
She describes that, based on data patients selected for fitness and comorbitiies irrespective of age, the progression-free and overall survival of patients aged over 65 recommends ASCT as a treatment option.
Dr Pawlyn also spoke with ecancer at EHA in Madrid in 2017, here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.